Sun Pharmaceutical Industries has been granted permission by the DCGI to produce and distribute a generic semaglutide injection for chronic weight management under the brand name Noveltreat. This key approval places Sun Pharma-India’s largest drugmaker by revenue-in a strong position to cash in on the rapidly growing GLP-1 therapy market when Novo Nordisk’s formulation patent expires in India in March 2026. The company was earlier approved for a semaglutide injection for type 2 diabetes, which is also due for a similar post-patent launch.
The Approaching Generic Tide:
Sun Pharmaceutical Industries, has received an important regulatory milestone as the Indian Drug Controller General of India gave approval for their generic semaglutide injectable product Noveltreat. It will help them prepare for launching their product once the secondary patent covering semaglutide formulation and delivery by Novo Nordisk expires in India in March 2026. This comes after an interim high court ruling in December 2025 that enabled Sun Pharma to start manufacturing their semaglutide formulation for export purposes but prohibited their local sales until the patent’s end. The company’s stock traded at Rs1,630.80 as of January 23, 2026. It exhibited an increase of 1.33% over the past trading sessions.
Clinical Validation and Market Potential:
The DCGI’s decision is underpinned by a Phase III clinical trial conducted in India, validating the efficacy and safety of Noveltreat for chronic weight management. The drug will be offered in five strengths, administered weekly via a prefilled pen for enhanced patient convenience. Semaglutide, a GLP-1 receptor agonist, is a sought-after therapeutic for obesity and type 2 diabetes, often leading to significant weight loss when combined with lifestyle changes. This segment is experiencing explosive growth in India, with the GLP-1 receptor agonist market projected to expand from approximately USD 110.55 million in 2024 to an estimated USD 579 million by 2030, driven by a CAGR of over 34%. The weight-loss drug market alone surged 115% in 2025 to ₹1,230 crore (approx. USD 148 million).
Addressing India’s Chronic Disease Burden:
Currently, India is grappling with a serious and increasing health crisis of obesity and diabetes and thus presents a large clinical need to address these conditions. The National Family Health Survey-5 (NFHS-5) statistics have revealed that one-fourth of Indians aged 15 to 49 are suffering from overweight and obesity. More statistics have also revealed that the percentage of obese female and male populations in India are 6.4 and 4.0, respectively. On the other hand, an ICMR-INDIAB study stated that close to 101 million individuals across India are suffering from diabetes and are facing clinical challenges to achieve appropriate levels of Hb1c. Such epidemiology highlights the urgent clinical and therapeutic opportunity to utilize semaglutide as a drug.
Competitive Scenario and Outlook:
Sun Pharma’s entry into the generic semaglutide market will be at a time when competition is increasing. Several Indian pharma companies, including Dr. Reddy’s Laboratories, Alkem Laboratories, and Cipla, have already received regulatory approvals or are at an advanced stage of development for their generic semaglutide versions. Dr. Reddy’s said it intends to launch its generic Ozempic in March 2026. The prices are likely to fall precipitously with the patent expiry, first by 30-50%, and over time by 70-75%, which should accelerate adoption among a wider patient population. According to analysts, generic semaglutide can unlock more than Rs 50 billion revenue opportunity across India and other markets in the next 12-15 months after the patent expiry. Sun Pharma, with its leadership in cardiometabolic therapies and extensive market reach, is well-placed to capture a large share of this growing market. The P/E ratio stands at about 37.05, and the market capitalization at ₹3.92 lakh crore as of January 2026.
